Compare Carvana Co (CVNA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs 10X Genomics Inc — how do they compare? Carvana Co trades at $71.89 (market cap $79.17B), while 10X Genomics Inc trades at $56.97 (market cap $7.61B). The key difference: Carvana Co is far larger — about 10.4× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| CVNA | TXG | |
|---|---|---|
Market Cap | $79.17B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $58.57 |
52-Week Low | $56.27 | $11.34 |
Enterprise Value | $81.65B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.
Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
